Thymosin Alpha-1 (5 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Thymosin Alpha-1 (also written Tα1, and known clinically as thymalfasin) is a 28-amino-acid peptide that occurs naturally in thymic tissue. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed across the published literature, not a recommendation for use in humans or animals.

For a 5 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of approximately 1.67 mg/mL (about 1,670 mcg/mL). At that fill, every 1 unit on a U-100 insulin syringe equals 0.01 mL and delivers roughly 16.7 mcg, so a 500 mcg measurement falls at about 30 units (0.30 mL). A larger 3 mL diluent volume is used here deliberately, since it keeps each daily microgram draw above the low-accuracy end of an insulin syringe.

Standard (Gradual) Titration Schedule

The gradual schedule eases the daily amount upward over the first week before settling at the maintenance level used through most published protocols. A short lead-in step is a common way to model tolerability before holding the higher dose.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, which helps avoid foaming.
3. Swirl or roll the vial gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (~1.67 mg/mL) and the reconstitution date.
5. Refrigerate at 2–8 °C between uses, protect from light, and draw subsequent volumes with a fresh sterile syringe each time.

Extended (Twice-Weekly) Reference Schedule

Beyond the daily microgram model, much of the clinical hepatitis literature instead used a higher milligram dose given only twice per week. This alternate schedule is included for completeness and reflects the dosing seen in those trials rather than an escalation of the daily protocol.

Supplies Needed

• Thymosin Alpha-1 vials (5 mg): ~6 vials for an 8-week daily run at 300–500 mcg; budget more for a 12–16 week extension.
• Insulin syringes (U-100, 1 mL): ~56 for an 8-week daily schedule (one fresh syringe per draw).
• Bacteriostatic water (10 mL): two bottles cover an 8-week run (about 18 mL of diluent total).
• Alcohol swabs: roughly two 100-count boxes for an 8-week daily schedule (about two swabs per day).

Protocol Overview

• Research goal: model immune modulation via T-cell maturation and cytokine signalling.
• Schedule: once-daily subcutaneous administration in the daily microgram model.
• Dose band: 300–500 mcg daily; 1.6 mg twice weekly in the clinical milligram model.
• Fill: 5 mg lyophilized, reconstituted to ~1.67 mg/mL with 3 mL diluent.
• Storage: 2–8 °C dry short term (−20 °C long term); 2–8 °C once reconstituted.

Dosing Protocol Notes

• Hold the 300 mcg lead-in for about a week before stepping to the 500 mcg maintenance level.
• Keep administration on a fixed daily cadence and at a consistent time for steady exposure modelling.
• Cycles typically run 8–12 weeks, with some protocols extending to 16 weeks.
• The larger 3 mL fill is intentional — it lifts each microgram draw above the low end of an insulin syringe, where accuracy degrades.

Storage Instructions

Keep sealed lyophilized vials at 2–8 °C for short-term storage or −20 °C for longer holds, protected from light. Once reconstituted, refrigerate at 2–8 °C and use within about 7 days. Avoid repeated freeze-thaw cycles, allow refrigerated solution to warm slightly before drawing, and discard if the solution becomes cloudy or discoloured.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Keep each draw above roughly 20% of the syringe's capacity where possible to preserve dosing accuracy.
• Document each draw — date, volume, remaining material — for reproducibility.

How Thymosin Alpha-1 Works

Thymosin Alpha-1 is a naturally occurring thymic peptide that influences immune function through several converging pathways. It supports the maturation and differentiation of T-cells, strengthens dendritic cell activity, and encourages production of signalling cytokines such as interferon-alpha and interleukin-2. Rather than broadly suppressing or stimulating the immune system, it is characterised in the literature as a modulator that helps coordinate the cellular arm of the immune response, which is why it has been studied most in immunocompromised and chronic-infection contexts.

Reported Benefits & Side Effects

Benefits observed in studies

• Enhanced T-cell function and broader immune competence in immunocompromised models.
• Documented activity in chronic hepatitis B and C, where it was studied as an adjunct to support immune response.
• Meta-analysis signal of reduced mortality among moderate-to-critical COVID-19 patients.
• A consistently described "excellent" safety profile across long-running courses.

Side effects reported

• Most common: mild injection-site irritation such as redness or transient discomfort.
• Doses up to 1.6 mg twice weekly for 6–12 months were well tolerated.
• Experimental exposure up to 16 mg over 12 months showed no significant toxicity.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then withdraw and apply gentle pressure.
• Rotate sites systematically across the abdomen, thighs and upper arms to avoid lipohypertrophy, and dispose of sharps in an approved container.

References

Related Protocols